Comparison of inflation of third dose diphtheria tetanus pertussis (DTP3) administrative coverage to other vaccine antigens |
| |
| Institution: | 1. Rollins School of Public Health, Emory University, 1518 Clifton Road NE, Atlanta, GA 30322, USA;2. National Center for Child and Adolescent Health, Ministry of Health, Francisco de P. Miranda 177, Lomas de Plateros, Álvaro Obregón, 01600 Mexico City, Mexico;3. Sanofi Pasteur, Avenida Universidad 1738, Colonia Coyoacán, 04000 Mexico City, Mexico;4. Emory University School of Medicine, 1648 Pierce Drive NE, Atlanta, GA 30322, USA;1. Department of Epidemiology, Biostatistics & Occupational Health, McGill University, 1020 Pine Ave., West Montreal, QC H3A 1A2, Canada;2. Research Institute of the McGill University Health Centre, 1001 Decarie Boul., Montreal, QC H4A 3J1, Canada;3. Infection Prevention & Control Unit, Department of Medical Microbiology, CHU Sainte-Justine, University of Montreal, 3175 Cote Sainte-Catherine, Montreal, QC H3T 1C5, Canada;4. Direction des risques biologiques et de la santé au travail, Institut de santé publique du Québec, 945 Avenue Wolfe, Québec, QC G1V 5B3, Canada;5. Division of Paediatric Infectious Diseases, CHU Sainte-Justine, University of Montreal, 3175 Cote Sainte-Catherine, Montreal, QC H3T 1C5, Canada;6. Department of Paediatrics, University of Sherbrooke, 3001, 12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada;7. Department of Microbiology, Infectious Diseases and Immunology, University of Montreal, C.P. 6128, succ. Centre-ville, Montréal, Québec H3C 3J7, Canada;1. Service d’hygiène, épidémiologie et prévention, hôpital Edouard-Herriot, hospices civils de Lyon, place d’Arsonval, 69003 Lyon, France;2. Université de Lyon 1, 69000 Lyon, France;3. Groupement de laboratoires de biologie médicale libéraux DYOMEDEA, 69005 Lyon, France;4. Sanofi Pasteur MSD, 69007 Lyon, France;1. State Government Department of Health and Human Services, 50 Lonsdale Street, Melbourne, Victoria, Australia;2. Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia;3. School of Public Health, The University of Queensland, Brisbane, Queensland, Australia;4. UQ Child Health Research Centre, School of Medicine, The University of Queensland, Brisbane, Queensland, Australia;1. Vaccine and Immunisation Research Group, Murdoch Childrens Research Institute, Australia;2. Department of General Medicine, The Royal Children’s Hospital, Australia;3. School of Population and Global Health, The University of Melbourne, Australia;4. Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Western Australia, Australia;5. Sir Walter Murdoch School of Public Policy and International Affairs, Murdoch University, Australia;6. Sydney School of Public Health, Sydney Medical School, University of Sydney, Australia;7. National Centre for Immunisation Research and Surveillance, Australia;8. The Alfred Hospital, Royal Women’s Hospital and Monash Health and Monash University, Australia;9. Women’s and Children’s Hospital and Robinson Research Institute, The University of Adelaide, South Australia, Australia;10. Clinical Epidemiology and Biostatistics Unit, Murdoch Childrens Research Institute, Australia;1. Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre, and the Nova Scotia Health Authority, Halifax, Nova Scotia, Canada;2. School of Nursing, Dalhousie University, Halifax, Nova Scotia, Canada;3. Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada;4. School of Nursing, St. Francis Xavier University, Antigonish, Nova Scotia, Canada;5. Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada;6. Department of Community Health and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada;7. Department of Microbiology & Immunology, Dalhousie University, Halifax, Nova Scotia, Canada |
| |
| Abstract: | Third dose diphtheria tetanus pertussis (DTP3) administrative coverage is a commonly used indicator for immunization program performance, although studies have demonstrated data quality issues with administrative DTP3 coverage. It is possible that administrative coverage for DTP3 may be inflated more than for other antigens. To examine this, theory, we compiled immunization coverage estimates from recent country surveys (n = 71) and paired these with corresponding administrative coverage estimates, by country and cohort year, for DTP3 and 4 other antigens. Median administrative coverage was higher than survey estimates of coverage for all antigens (median differences from 26 to 30%), however this difference was similar for DTP3 as for all other antigens. These findings were consistent when countries were stratified by income level and eligibility for Gavi funding. Our findings demonstrate that while country administrative coverage estimates tend to be higher than survey estimates, DTP3 administrative coverage is not inflated more than other antigens. |
| |
| Keywords: | Immunization Vaccine Data Coverage DTP3 Estimates |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
